CEO’s comments

“Through an oversubscribed right issue, our shareholders have showed great confidence in our business and we now have the strength to continue developing our three projects – anti-alpha-11, IdeS and HMD-301 towards the next value-generating goals. We have taken a major step in our IdeS project and completed the transfer of our internally developed production process to a contract manufacturing organization. The next step in this work is to produce a full-scale batch for our planned pre-clinical toxicity and safety studies. The goal for project IdeS is to submit an application to conduct a clinical phase I study to the Medical Products Agency during the first half of 2011.

“Our partnership agreements with Alere (formerly Inverness Medical Innovations) and Axis-Shield are both proceeding according to plan with respect to both time and development activities. Alere has generated a large number of anti-alpha-11 antibodies that Hansa Medical is now characterizing, evaluating and gaining patent protection on. This evaluation work is extensive, and we will devote much of the autumn to carefully selecting a small number of antibodies for further development. In recent months, the Axis-Shield collaboration has focused on further development of Hansa Medical’s analysis prototype, HMD-301, for diagnosis and prognosis of severe sepsis. In addition, extensive planning work was conducted to have all logistical pieces in place prior to the clinical registration trial of HMD-301. The study will be conducted at emergency clinics in Sweden and the US. The clinical study is planned to start during autumn 2010, and the goal of achieving market launch of an initial version of the analysis method by the end of 2011 remains.” Emanuel Björne, CEO of Hansa Medical (publ).

 (For complete Interim report, se attached PDF)